Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
about
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesProfile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patientsIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseAssessment of pancreatic β-cell function: review of methods and clinical applicationsGemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes MellitusUpdate on the treatment of type 2 diabetes mellitusDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsSaxagliptin overview: special focus on safety and adverse effectsA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsPaediatric type 2 diabetes in China-Pandemic, progression, and potential solutions.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus.Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonThe evolving place of incretin-based therapies in type 2 diabetesRole of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataTherapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsSaxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitusEfficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Saxagliptin for type 2 diabetesTherapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.The role of incretin therapy at different stages of diabetes.Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
P2860
Q26765047-4058CA7C-D974-4669-9602-E594C4864EBAQ26824239-6EA4A1DC-B505-4D03-8E35-E8955DF043ABQ26827183-CA39B8B4-FB69-4E29-ABDC-AB6A7B918EA3Q26829445-D34E48D8-B897-4EBE-8BFA-3C759C47C5DCQ28066209-D1A7D9F1-E4E0-4CF1-8B9E-C295DE276F33Q28073342-45FBAE7D-C7E5-445D-9EA7-5FAF0CC293FDQ28238585-02093B64-2DB8-4EC6-83A4-ABC052FBDFE8Q28278863-088AC3C1-8030-41E2-9BA4-DACF4DE3FBE8Q28282265-61E190CE-74CB-410E-87DA-EC11A1E9D7FFQ28294225-A6CAB08A-E684-46F3-9236-C8CBDDF8EC0DQ30235154-CE5D579E-ECE7-4215-A0A3-6C8C81FF4FB1Q30846870-D74694DC-E02A-4297-81CA-5CCE1FDB3D91Q33412360-AD79FD4C-3C98-4F3C-9CB7-C68648F4289EQ33535235-3C68CDFA-3EBA-4539-9015-6298CAFEDF15Q33732627-AEC2BCB1-5ABF-4051-BE5A-1D069AAD2C1DQ33785197-572B299D-08C5-4695-A6DA-70AAC0CA8549Q33866808-A2085416-FE5E-4D38-B1B4-600B1693C18BQ33886865-30365A47-CDF5-420E-9122-E710B2A83977Q34068749-2319FDC6-5EB3-4E59-A5BE-37882F2449E8Q34078449-100E8588-5F1E-4065-97AD-16B19C3C8380Q34128612-F93FA566-52C0-40DE-A30D-E15B1C15A1ADQ34133889-5F5B0052-53B6-442B-AE46-D7DD062703EBQ34239784-30E51D39-1392-421D-B887-402F39A17630Q34273302-AEAF1C08-FCA4-4081-BF7A-EEEFFA057141Q34374336-A22C9C88-F95C-4A89-A40D-3316C247EB3DQ34374350-9924C3A7-048E-4160-86FF-73694CF9C69BQ34454269-5DF5C8EF-53B6-4EE4-BEA0-FC156257CFD0Q34620486-C29A1B00-6BAC-4126-9D0E-DBD9B5F67678Q34750027-65DC0E78-54E8-42FF-9996-28C9A98AE9E0Q34783302-353B01AC-EF71-4F97-8E97-C182A2F47690Q35026483-CC9F761D-DA82-4D31-9AF6-F003C29EDB3AQ35200252-BD18A10B-1233-4482-917B-1D870AD3AD45Q35236019-4B652212-4230-4C11-A081-E3A0BB195562Q35411329-CF22AADB-8C93-45E5-98CE-0BDE754295A1Q35717211-F852579E-E17D-4EB4-8D05-D548CDD22B82Q35760288-F22E6D6E-6ED8-45D3-A36B-2FFD267AA8C9Q35808043-C8E72ACA-6BF3-4B50-8E4F-F73E98AB1AE5Q35906506-A3ECA23D-E53B-4BF9-A5FD-3104CA430D9CQ35928257-D23753F2-AD70-4030-9C2E-7445661CA23AQ36064235-804B3E7A-1973-4B11-B319-139DB7CA9971
P2860
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@en
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@nl
type
label
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@en
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@nl
prefLabel
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@en
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@nl
P2093
P1476
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
@en
P2093
C Aguilar-Salinas
CV181-011 Study Investigators
J Rosenstock
P304
P356
10.1185/03007990903178735
P407
P577
2009-10-01T00:00:00Z